Belozeroff V - Search Results

1

Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.

Stollenwerk B, Iannazzo S, Cooper K, Belozeroff V. Stollenwerk B, et al. Among authors: belozeroff v. J Med Econ. 2017 Oct;20(10):1110-1115. doi: 10.1080/13696998.2017.1360309. Epub 2017 Aug 14. J Med Econ. 2017. PMID: 28803497 Free article.

2

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V. Stollenwerk B, et al. Among authors: belozeroff v. Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-2. Pharmacoeconomics. 2018. PMID: 29392552 Free article. Clinical Trial.

3

Hemodialysis patients' preferences for the management of secondary hyperparathyroidism.

Hauber B, Caloyeras J, Posner J, Brommage D, Belozeroff V, Cooper K. Hauber B, et al. Among authors: belozeroff v. BMC Nephrol. 2017 Jul 28;18(1):254. doi: 10.1186/s12882-017-0665-8. BMC Nephrol. 2017. PMID: 28750605 Free PMC article.

4

Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis.

Lozano-Ortega G, Waser N, Bensink ME, Goring S, Bennett H, Block GA, Chertow GM, Trotman ML, Cooper K, Levy AR, Belozeroff V. Lozano-Ortega G, et al. Among authors: belozeroff v. J Comp Eff Res. 2018 Jul;7(7):693-707. doi: 10.2217/cer-2018-0015. Epub 2018 May 15. J Comp Eff Res. 2018. PMID: 29762046 Free article.

5

Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study.

Levy AR, Xing S, Brunelli SM, Cooper K, Finkelstein FO, Germain MJ, Kimel M, Platt RW, Belozeroff V. Levy AR, et al. Among authors: belozeroff v. Am J Kidney Dis. 2020 Mar;75(3):373-383. doi: 10.1053/j.ajkd.2019.07.013. Epub 2019 Oct 16. Am J Kidney Dis. 2020. PMID: 31629575

6

Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.

Belozeroff V, Lee A, Tseng S, Chiroli S, Campbell JD. Belozeroff V, et al. J Med Econ. 2013 Sep;16(9):1154-62. doi: 10.3111/13696998.2013.826665. Epub 2013 Aug 6. J Med Econ. 2013. PMID: 23869940 Free article. Clinical Trial.

7

Healthcare use and costs before and after parathyroidectomy in patients on dialysis.

Belozeroff V, Cooper K, Hess G, Chang CL. Belozeroff V, et al. BMC Health Serv Res. 2013 Jul 2;13:248. doi: 10.1186/1472-6963-13-248. BMC Health Serv Res. 2013. PMID: 23819622 Free PMC article.

8

Association of cinacalcet adherence and costs in patients on dialysis.

Lee A, Song X, Khan I, Belozeroff V, Goodman W, Fulcher N, Diakun D. Lee A, et al. Among authors: belozeroff v. J Med Econ. 2011;14(6):798-804. doi: 10.3111/13696998.2011.627404. Epub 2011 Oct 11. J Med Econ. 2011. PMID: 21988567 Free article.

9

Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States.

Boer R, Lalla AM, Belozeroff V. Boer R, et al. Among authors: belozeroff v. J Med Econ. 2012;15(3):509-20. doi: 10.3111/13696998.2012.664799. Epub 2012 Feb 21. J Med Econ. 2012. PMID: 22313328 Free article.

10

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH. Belozeroff V, et al. Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007. Epub 2015 Oct 9. Value Health. 2015. PMID: 26686794 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters